

# Dr. Frank C. Richardson, DVM, PhD, DABT

Principal Toxicologist

## Executive Summary:

---

Experienced pharmaceutical development professional with progressive large pharmaceutical and biotechnology experience in: toxicologic assessment of drug candidates, biomarker development, and animal care and use.

Skilled in resource limited management and conduct of all aspects of preclinical toxicology and biomarker development from discovery to product registration with emphasis on oncology and antiviral compounds. Partnered with outside companies to develop and implement biomarker strategies. Establishes acceptable daily exposure and occupational exposure levels for drugs and chemicals. Develops creative solutions and strategic guidance specific to company needs, resources and goals and improvements to ongoing processes in collaborative diverse team-based environments.

## Education:

---

- BS, Life Sciences, Massachusetts Institute of Technology
- DVM, Veterinary Medicine, Iowa State University
- PhD, Experimental Pathology, Duke University

## Work History:

---

**Principal Toxicologist**, Affygitly Solutions, LLC – Broomfield, CO

- Establish occupational exposure levels and acceptable daily exposures limits to pharmaceutical and chemical manufacturers.

**Principle Research Fellow** (Vice-President Level),

**Toxicology and Molecular Markers**, OSI Pharmaceuticals – Boulder, CO

- Managed \$8M toxicology and biomarker program budget supporting 8 toxicology studies, biomarker components of 10 clinical studies, and development of 2 companion diagnostics programs.
- Completed the analysis of biomarkers in RADIANT a world-wide 974 patient clinical trial in adjuvant NSCLC the largest single biomarker study to date in this indication. Presented the final biomarker data for RADIANT in an oral presentation to the World Congress on Lung Cancer, Amsterdam 2011.
- Served as biomarker representative on the SATURN (Tarceva for Maintenance in NSCLC) OSI fling team and the EURTAC (Tarceva in first-line NSCLC) regulatory team. Represented OSI at SATURN ODAC

meeting. Authored biomarker section of briefing document for the SATURN post approval commitment study which was presented and accepted by FDA.

- Chaired the OSI, Roche, Genentech Tripartite Biomarker Team. Drafted, presented, and gained approval from the Global Development Committee representing the 3 pharmaceutical companies of plans for the biomarker strategy and the development of companion diagnostics for Tarceva. Prioritized and coordinated the prioritization of biomarker testing in ongoing and planned Tarceva clinical trials. Completed investigative studies on the value and utility of EGFR IHC for detection of EGFR mutations. Contributed to the overall assessment of the utility of EGFR IHC, EGFR FISH, EGFR mutation and Kras mutations as predictive biomarkers for Tarceva in NSCLC (presented at WCLC 2011).
- Supervised a division of from 5 to 20 individuals spread between Boulder CO and Oxford England that initiated and completed over 100 internal or external GLP, investigative and discovery safety assessment studies including 5 INDs including oncology, diabetes / obesity, asthma, and macular degeneration compounds.
- Designed, conducted, and completed late-stage Tarceva toxicology studies, authored Preclinical NDA Section for Tarceva in 2nd line NSCLC and served as Lead Toxicologist for Tarceva at ODAC and FDA meetings that lead to successful approval in pancreatic cancer.
- Managed GLP and AAALAC Toxicology and Animal Care Division of over 20 people overseeing 2 successful FDA and AAALAC site inspections.
- Initiated OSI Biomarkers Program from concept to evaluation of over 20 biomarkers in more than 15 clinical trials covering 5 different compounds including development companion diagnostic tests, pharmacodynamics, predictive, prognostic, and response biomarkers.
- Designed, conducted, and published or presented research in over 20 papers / oral presentations / posters to the American Association of Cancer Research, American Association of Clinical Oncologists, Society of Toxicology, International Association of Study of Lung Cancer.

**Director, Toxicology Safety Assessment and Animal Facility, Gilead Pharmaceuticals – Boulder, CO**

- Managed a division responsible for the preclinical safety assessment of Gilead / Nexstar compounds, conducting mechanistic studies related to toxicities of candidate compounds and the appropriate care and use of animals.
- Designed, conducted, and completed of toxicology studies and authored preclinical the section of the NDA for Adefovir and Tenofovir NDA.
- Conducted and published 9 research studies on the mechanism of toxicity and action of nucleoside analog antiviral / anticancer agents.

**Research Scientist, Eli Lilly and Company – Indianapolis, IN**

- Responsible for conducting and publishing leading edge research into the mechanisms of compound induced carcinogenesis, mitochondrial toxicity, and anti-cancer efficacy, managing Lilly candidate

compounds through toxicology evaluations, and initiating processes of biomarker tissue collection and analysis.

- Initiated and completed conversion of the Nexstar / Gilead toxicology and animal facility to a GLP compliant and AAALAC approved program and facility evidenced by successful FDA site inspection and AAALAC accreditation.
- Designed, conducted, and published or presented over 30 studies to understand mechanisms of carcinogenesis of potential Lilly therapeutics, the mechanism of action of anti-cancer nucleoside analogs, the mechanism of toxicity of the anti-viral agent fialuridine (FIAU); the latter results used by the Institute of Medicine in evaluating the mechanism of lethal toxicity of FIAU in clinical trials. Toxicology project leader for antibody-toxin conjugate for the treatment of skin cancer in partnership with a biotechnology partner.

### Training and Courses:

---

- Center for Creative Leadership Development
- Charles River Short Course
- Results Through People
- Society of Toxicology Continuing Education
- Midwest Toxicology Course
- Professional Affiliations
- American Association for Cancer Research
- Society of Toxicology
- Diplomat of American Board of Toxicology

### Publications:

---

- RICHARDSON, F. C., DYROFF, M. C., BOUCHERON, J. A., AND SWENBERG, J. A. (1985). Differential repair of O4 -alkylthymidine following exposure to methylating and ethylating hepatocarcinogenesis. *Carcinogenesis* 6, 625-629.
- SWENBERG, J. A., RICHARDSON, F. C., BOUCHERON, J. A., AND DYROFF, M. C. (1985). Relationships between DNA adduct formation and carcinogenesis. *Environ. Health Perspect.* 62, 177-186.
- BELINSKY, S. A., WHITE, C. M., BOUCHERON, J. A., RICHARDSON, F. C., SWENBERG, J. A., AND ANDERSON, M. A. (1986). Accumulation and persistence of DNA adducts in respiratory tissue following multiple administration of the tobacco specific carcinogen 4-[N-methyl-N-nitro-samine]-1- (3-pyridyl)-1-butanone (NNK). *Cancer Res.* 46, 1280-1284.

- DYROFF, M. C., RICHARDSON, F. C., POPP, J. A., BEDELL, M. A., AND SWENBERG, J. A. (1986). Correlation of O4-ethyldeoxythymidine accumulation, hepatic initiation, and hepatocellular carcinoma induction in rats continuously administered diethylnitrosamine. *Carcinogenesis* 7, 241-246.
- RICHARDSON, F. C., BOUCHERON, J. A., DYROFF, M. C., POPP, J. A., AND SWENBERG, J. A. (1986). Biochemical and morphological studies of heterogeneous lobe responses in hepatocarcinogenesis. *Carcinogenesis* 7, 247-251.
- RICHARDSON, F. C. AND SWENBERG, J. A. (1987). Evaluating the utility of molecular dosimetry and cell replication in carcinogenic risk assessment. *CIIT Activities* 7.
- RICHARDSON, F. C., BEAUCHAMP, R. O. JR., AND SWENBERG, J. A. (1987). Properties and biological consequences of alkylpyrimidine deoxyribonucleosides. *Pharmacol. Therapeut.* 34, 181-213.
- BOUCHERON, J. A., RICHARDSON, F. C., AND SWENBERG, J. A. (1987). Molecular dosimetry of O4-ethylthymidine in rats chronically exposed to diethylnitrosamine. *Cancer Res.* 47, 1577-1581.
- RICHARDSON, K. K., RICHARDSON, F. C., SWENBERG, J. A., AND SKOPEK, T. R. (1987). DNA base changes induced by methylnitrosourea and ethylnitrosourea mutagenesis in *E. coli*. *P. Nat. Acad. Sci. USA.* 84, 344-348.
- RICHARDSON, K. K., CROSBY, R. M., RICHARDSON, F. C., AND SKOPEK, T. R. (1987). DNA base changes induced following in vivo exposure of unadapted, adapted, or ada-*Escherichia coli* to N-methyl-N'-nitro-N-nitrosoguanidine. *Mol. Gen. Genet.* 209, 526-532.
- SWENBERG, J. A., RICHARDSON, F. C., TYERYAR, L., DEAL, F., AND BOUCHERON, J. A. (1987). The molecular dosimetry of DNA adducts formed by continuous exposure of rats to alkylating hepatocarcinogens. *Prog. Exp. Tumor Res.* 31, 42-51.
- SWENBERG, J. A., RICHARDSON, F. C., BOUCHERON, J. A., DEAL, F. H., AND BELINSKY, S. A. (1987). High- to low-dose extrapolation: Critical determinants involved in the dose response of carcinogenic substances. *Environ. Health Perspect.* 76, 57-63.
- RICHARDSON, F. C., MORGAN, P. H., BOUCHERON, J. A., DEAL, F. H., AND SWENBERG, J. A. (1988). Hepatocyte initiation during continuous administration of diethylnitrosamine and 1,2-sydimethylhydrazine. *Cancer Res.* 48, 988-992.
- RICHARDSON, F. C., BOUCHERON, J. A., SKOPEK, T. R., AND SWENBERG, J. A. (1989). Formation of O6-methyldeoxyguanosine at specific sites in a synthetic deoxyribonucleotide designed to resemble a known mutagenic hotspot. *J. Biol. Chem.* 264, 838-841.
- DEAL, F. H., RICHARDSON, F. C., AND SWENBERG, J. A. (1989). Dose response of hepatocyte replication following continuous exposure to diethylnitrosamine. *Cancer Res.* 49, 6985-6988.
- RICHARDSON, F. C. AND RICHARDSON, K. K. (1990). Sequence dependent formation of alkyl DNA adducts: A review of methods, results, and biological correlates. *Mutat. Res.* 233, 127-138.

- CATTLEY, R. C., DIETZE, S. R., RICHARDSON, F. C., AND POPP, J. A. (1990). Detection of 5-hydroxymethyl-2'-deoxyguanosine in DNA from calf thymus, Hela cells, and rat liver nuclei. *Nucleos. Nucleot.* 9, 179-188.
- RICHARDSON, F. C. (1991). DNA adducts in molecular toxicology. *FASEB. New Horizons in Molecular Toxicology*.
- RICHARDSON, F. C. AND RICHARDSON, K. K. (1991). Alterations in DNA-restriction enzyme interactions by O4-alkyldeoxythymidines. *Mol. Carcinogen.* 4, 162-168.
- RICHARDSON, F. C., RICHARDSON, K. K., KROIN, J. S., AND HERTEL, L. W. (1992). Synthesis and restriction enzyme digestion of oligonucleotides containing the anti-cancer drug 2', 2'-difluorodeoxycytidine. *Nucleic Acids Res.* 20, 1763-1768
- ANDERSON, N. L., COPPLE, D. M., BENDELE, R. A., PROBST, G. S., AND RICHARDSON, F. C. (1992). Covalent protein modifications and gene expression changes in rodent liver following administration of methapyrilene. A study using two-dimensional electrophoresis. *Fund. Appl. Tox.* 18, 570-580.
- RICHARDSON, K. K., REXROAT, M. A., HELVERING, L. M., COPPLE, D. M., AND RICHARDSON, F. C. (1992). Temporal changes in the mutant frequency and mutation spectra of the 61st codon of the H-ras oncogene following exposure of B6C3F1 mice to NNitrosodiethylamine (DEN). *Carcinogenesis.* 13, 1277-1279.
- RICHARDSON, K. K., HELVERING, L. M., COPPLE, D. M., REXROAT, M. A., LINVILLE, D. W., ENGELHARDT, J. A., TODD, G. C., AND RICHARDSON, F. C. (1992). Genetic alterations in the 61st codon of the H-ras oncogene isolated from archival sections of hepatic hyperplasias, adenomas and carcinomas in control groups of B6C3F1 mouse bioassay studies conducted from 1979-1986. *Carcinogenesis.* 13, 935-941.
- RICHARDSON, F. C., HORN, D. M., AND EACHO P. I. (1992). Effects of methapyrilene on DNA synthesis in mice and rats following continuous dietary exposure. *Carcinogenesis.* 13, 2453-2457.
- COPPLE, D. M., RUSH, G. F., AND RICHARDSON, F. C. (1992). Effects of methapyrilene measured in mitochondria isolated from naive and methapyrilene-treated rat and mouse hepatocytes. *Toxicol. Appl. Pharm.* 116, 10-16.
- RICHARDSON, F. C., STROM, S. C., COPPLE, D. M., BENDELE, R. A., PROBST, G. S., AND ANDERSON, N. L. (1993). Comparisons of protein changes in human and rodent hepatocytes induced by the rat specific carcinogen, methapyrilene. *Electrophoresis.* 14, 157-161.
- OBERLY, T. J., SCHEURING, J. C., RICHARDSON, K. K., RICHARDSON, F. C., AND GARRIOTT, M. L. (1993). The evaluation of methapyrilene for bacterial mutation with metabolic activation by Aroclor-induced, methapyrilene-induced and noninduced rat liver S9. *Mutat. Res.* 229, 77-84.
- HELVERING, L., RICHARDSON, K., HORN, D., WIGHTMAN, K., HALL, R., SMITH, W., ENGELHARDT, J., AND RICHARDSON, F. C. (1993). Expression of TRPM-2 during involution and regeneration of the rat liver. *Can. Lett.* 71, 133-142.

- SCHY, W. E., HERTEL, L. W., KROIN, J. S., BLOOM, L. B., GOODMAN, M. F., AND RICHARDSON F. C. (1993). Effect of template-located 2',2'- difluorodeoxycytidine on the kinetics of base insertion by a DNA polymerase. *Cancer Res.* 53, 4582-4587.
- RICHARDSON, K. K. and RICHARDSON, F. C. (1993). Analysis of point mutations in DNA using polymerase chain reaction (PCR) and DNA sequencing. in "Current Topics in Mol. Genet." eds. Council of Scientific Research Trends, India. 2, 87-99.
- RICHARDSON, F. C., HORN, D. M., AND ANDERSON, N. L. (1994). Dose-responses in rat hepatic protein modification and expression following exposure to the rat hepatocarcinogen methapyrilene. *Carcinogenesis* 15, 325-329.
- HELVERING, L. M., RICHARDSON, F. C., HORN, D. M., REXROAT, M. A., ENGELHARDT, J. A., and RICHARDSON, K. K. (1994). H-ras 61st codon activation in archival proliferative hepatic lesions isolated from female B6C3F1 mice exposed to the leukotriene D4-antagonist, LY171883. *Carcinogenesis* 15, 331-333.
- RICHARDSON, F. C., ENGELHARDT, J. A., AND BOWSHER, R. R (1994). Fialuridine (FIAU) accumulates in DNA of dogs, monkeys, and rats following long-term oral administration. *P. Nat. Acad. Sci. USA* 91, 12003-12007.
- HORN, D. M., JORDAN, W. H., HOLLOWAY, D., SCHABERG, E., SMITH, W., AND RICHARDSON, F. C. (1995). Dose-dependent induction of GSTP+ foci by the hepatocarcinogen methapyrilene in the liver medium term bioassay. *Fund. Appl. Tox.* 29, 194-197.
- ANDERSON, N. L., ESQUER-BLASCO, R., RICHARDSON, F. C., FOXWORTHY P., and EACHO, P. (1995). The effects of peroxisome proliferators on protein abundances in mouse liver. *Toxicol. Appl. Pharm.* 137, 75-89.
- COLACINO, J. M., HORN, J. W., HORN, D. M., AND RICHARDSON, F. C. (1996) Incorporation of Fialuridine (FIAU) into mitochondrial DNA and effects of FIAU on the morphology of mitochondria in human hepatoblastoma cells. *Toxicology in vitro* 10, 297-303.
- STASCHKE, K. A., RICHARDSON, K. K., MABRY, T. E., BAXTER, A. J., SCHEURING, J. C., HUFFMAN, D. M., SMITH, W. C., RICHARDSON, F. C., AND COLACINO, J. M. (1996). Differential effects of the incorporation of I-(2-deoxy-2-fluoro-B-D-arabinofuranozyl)-5- iodouracil (FIAU) on the binding of the transcription factors, AP-1 and TFIID, to their cognate target DNA sequences. *Nucleic Acids Res.* 24, 4111-4116.
- HORN, D. M., NEEB, L. A., COLACINO, J. M. AND RICHARDSON, F. C. (1996). FIAU is phosphorylated and inhibits DNA synthesis but not protein synthesis in isolated rat mitochondria. *Antiviral Research* 34, 71-74
- TENNANT, B.C., BALDWIN, B.H., GRAHAM, L.A., ASCENZI, M.A., HORNBuckle, W.E., ROWLAND, P.H., TOCHKOV, I.A., YEAGER, A.E., COLACINO, J.M., LOPEZ, C., ENGELHARDT, J.A., BOWSHER, R.R.,

- RICHARDSON, F.C., LEWIS, W., COTE, P.J., KORBA, B.E., AND GERIN, J.L. (1998). Antiviral activity and toxicity of faluridine in the woodchuck model of hepatitis B virus infection. *Hepatology* 28, 179-191.
- RICHARDSON, F.C., TENNANT, B.C., MEYER, D.J., RICHARDSON, K.A., MANN, P.C., MCGINTY, G.R., WOLF, J.L., ZACK, P.M., AND BENDELE, R.A. (1999) An evaluation of the toxicities of 2'-fluorouridine and 2'-fluorocytidine-HCl in F-344 rats and woodchucks (*Marmota monax*) *Toxicologic Pathology* 27, 607-617.
  - RICHARDSON, F.C., KUCHTA, R.D., MAZURKIEWICZ, A., AND RICHARDSON, K.A (2000) Polymerization of 2'- fluoro- and 2'-O-methyl-dNTPs by human DNA polymerase  $\alpha$ , polymerase  $\gamma$  and primase, *Biochemical Pharmacology* 59, 1045-1052.
  - EMERSON, D.L., BENDELE, R., BROWN, E., CHIANG, S., DESJARDINS, J.P., DIHEL, L.C., GILL, S.C., HAMILTON, M., LERAY, J.D., MOON-MCDERMOTT, L., MOYNIHAN, K., RICHARDSON, F.C., TOMKINSON, B., LUZZIO, M.J., BACCANARI, D. (2000) Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. *Cancer Res.* 6, 2903-12.
  - DESJARDINS, J.P., ABBOTT, E.A., EMERSON, D.L., TOMKINSON, B.E., LERAY, J.D., BROWN, E.N., HAMILTON, M., DIHEL, L., PTASZYNSKI, M., BENDELE, R.A., AND RICHARDSON, F.C. (2001) Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice, *Anticancer Drugs* 12, 235-45.
  - BENDELE, R.A. AND RICHARDSON, F.C. (2002) Adefovir nephrotoxicity and mitochondrial DNA depletion. *Human Pathology* 33, 574.
  - RICHARDSON, F.C. ZHANG. C., LEHRMAN, S.R., KOC, H., SWENBERG, J.A., RICHARDSON, K.A., AND BENDELE, R.A. (2002) Quantification of 2'-fluoropyrimidines in rat and woodchuck DNA using HPLC/MS/MS. *Chemical Research in Toxicology*, 15(7):922-6.
  - DOBROVOLSKY, V.N., BUCCI, T., HEFLICH, R.H., DEJARDINS, J., AND RICHARDSON, F.C. (2002) Mice deficient for cytosolic thymidine kinase gene develop fatal kidney disease. *Molecular Genetics and Metabolism*, 78: 1-10.
  - BIESECKER, G., KARIMI, S., DESJARDINS, J., MEYER, D., ABBOTT, B., BENDELE, R.A., AND RICHARDSON, F. (2003). Tenofovir DF in rats, rhesus monkeys, or woodchucks, and adefovir dipivoxil in rats, do not elicit mitochondrial injury following sub-chronic or chronic administration. *Antiviral Res.* 2003 May; 58(3):217-25
  - RICHARDSON KA, VEGA TP, RICHARDSON FC, MOORE CL, ROHLOFF JC, TOMKINSON B, BENDELE RA, KUCHTA RD. (2004) Polymerization of the triphosphates of AraC, 2',2'-difluorodeoxycytidine (dFdC) and OSI-7836 (T-araC) by human DNA polymerase alpha and DNA primase. *Biochem Pharmacol.* Dec 15;68(12):2337-2346.
  - RICHARDSON FC, BLACK C, RICHARDSON K, FRANKS A, WELLS E, KARIMI S, SENNELLO G, HART K, MEYER D, EMERSON D, BROWN E, LERAY J, NILSSON C, TOMKINSON B AND BENDELE R (2005) Incorporation of OSI-7836 into DNA of Calu-6 and H460 xenograft tumors. *Cancer Chemotherapy and Pharmacology* Mar 55(3):213-21

- MING-SOUND TSAO, M.D., AKIRA SAKURADA, M.D., PH.D., JEAN-CLAUDE CUTZ, M.D., CHANG-QI ZHU, M.D., PH.D., SUZANNE KAMEL-REID, PH.D., JEREMY SQUIRE, PH.D., IAN LORIMER, PH.D., TONG ZHANG, M.D., NI LIU, M.SC., MANIJEH DANESHMAND, M.D., PAULA MARRANO, M.SC., GILDA DA CUNHA SANTOS, M.D., PH.D., ALAIN LAGARDE, PH.D., FRANK RICHARDSON, D.V.M., PH.D., LESLEY SEYMOUR, M.D., PH.D., MARLO WHITEHEAD, M.SC., KEYUE DING, PH.D., JOSEPH PATER, M.D., AND FRANCES A. SHEPHERD, M.D. (2005) Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome. New England Journal of Medicine. 353:133-144
- GARTON AJ, CREW AP, FRANKLIN M, COOKE AR, WYNNE GM, CASTALDO L, KAHLER J, WINSKI SL, FRANKS A, BROWN EN, BITTNER MA, KEILY JF, BRINER P, HIDDEN C, SREBERNAK MC, PIRRI C, O'CONNOR M, CHAN A, VULEVIC B, HENNINGER D, HART K, SENNELLO R, LI AH, ZHANG T, RICHARDSON F, EMERSON DL, CASTELHANO AL, ARNOLD LD, GIBSON NW. (2006) OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models. Cancer Res. Jan 15; 66:1015-24.
- HIRSCH FR, KABBINAVAR F, EISEN T, MARTINS R, SCHNELL FM, DZIADZIUSZKO R, RICHARDSON K, RICHARDSON F, WACKER B, STERNBERG DW, RUSK J, FRANKLIN WA, VARELLA-GARCIA M, BUNN PA JR, CAMIDGE DR. (2011). A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol. 29:3567-73.
- RICHARDSON F, YOUNG GD, SENNELLO R, WOLF J, ARGAST GM, MERCADO P, DAVIES A, EPSTEIN D, WACKER B (2012) The Evaluation of E-cadherin and Vimentin as Biomarkers of Clinical Outcomes Among 2nd- and 3rd- line Non-Small Cell Lung Cancer Patients Treated with Erlotinib. Anticancer Res. 32:1 Anticancer Res. 32:537-552.

APPROVALS	
COMPANY: AFFYGILITY SOLUTIONS LLC	
ORIGINATOR: _____	DATE: _____
QUALITY <i>Matthew</i> _____	DATE: 2026-05-13
MANAGEMENT <i>Don</i> _____	DATE: 2026-05-13
EFFECTIVE DATE: _____	2026-05-13



# CERTIFICATE *of* SIGNATURE

REF. NUMBER  
JTH2B-7MMKO-YMV8S-TPWZS

DOCUMENT COMPLETED BY ALL PARTIES ON  
13 MAY 2026 13:24:01  
UTC

## SIGNER

**DEAN CALHOUN**

EMAIL  
DCALHOUN@AFFYGILITY.COM


## TIMESTAMP

SENT  
13 MAY 2026 11:08:19

VIEWED  
13 MAY 2026 12:55:17

SIGNED  
13 MAY 2026 12:55:39

## SIGNATURE



IP ADDRESS  
151.253.30.203

LOCATION  
DUBAI, UNITED ARAB EMIRATES

## RECIPIENT VERIFICATION

EMAIL VERIFIED  
13 MAY 2026 12:55:17


**MATT GROESSL**

EMAIL  
MGROESSL@AFFYGILITY.COM

SENT  
13 MAY 2026 11:08:19

VIEWED  
13 MAY 2026 13:23:37

SIGNED  
13 MAY 2026 13:24:01



IP ADDRESS  
169.133.32.229

LOCATION  
AURORA, UNITED STATES

## RECIPIENT VERIFICATION

EMAIL VERIFIED  
13 MAY 2026 13:23:37

